Yorba Linda, Ca (PRWEB) August 09, 2017
The era of using extracellular vesicles (EVs) and exosomes for regenerative medicine applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized a cardiosphere-derived stem-like cell culturing process to manufacture secreted EVs present in conditioned medium for clinical studies.
Dr. Travis Antes, head of analytical development at Capricor Therapeutics Inc., will be the speaker for this presentation. He will review the strategies for clinical scale EV manufacturing, characterization of surface phenotypes and RNA cargo, molecular tools available to characterize extracellular vesicles, as well as building a pipeline for successful QC of these EVs for use in the clinic.
Antes earned a doctorate in Molecular and Cell Biology from the University of Texas in Dallas. In 2016, he joined the faculty at Cedars-Sinai Heart Institute as an associate professor and also became the Head of Analytical Development for Capricor Therapeutics Inc. His current research involves the characterization and development of therapeutic exosomes for a variety of disease applications.
This is a LabRoots hosted webinar, sponsored by Miltenyi Biotec. The webinar will take place on September 6, 2017, beginning at 9:00 a.m. PDT, 12:00 p.m. EDT. To learn more about this webinar, discover the continuing education credits offered, or to register for free, click here.
ABOUT CAPRICOR THERAPEUTICS
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of cardiac and other serious medical conditions. Capricor’s innovative technology builds upon a large body of scientific research and enables a novel approach to the treatment of diseases. They are one of the leading companies investigating the field of exosome science with plans to explore development of the exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non-cardiovascular areas.
ABOUT MILTENYI BIOTEC
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,500 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.